REG - Tissue Regenix Group - Distribution agreement for OrthoPure® XT in the UK

Tissue RegenixAnnouncement

10/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230710:nRSJ4187Fa&default-theme=true

RNS Number : 4187F  Tissue Regenix Group PLC  10 July 2023

Tissue Regenix Group plc

('Tissue Regenix', or the 'Company')

 

Multi-year distribution agreement for OrthoPure® XT signed in the UK

 

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces
that it has signed an exclusive distribution agreement with Joint Operations
Ltd ('Joint Operations'), a leading distribution business in the UK supplying
numerous products to treat joint injuries and help to preserve the joints of
the body, for the distribution of the Tissue Regenix OrthoPure® XT product
in the United Kingdom.

 

The initial agreement is for three years, subject to annual purchase minimums,
and Joint Operations will add OrthoPure® XT to its portfolio of products.
Joint Operations already distributes orthopaedic equipment to the National
Health Service and the private sector within the UK, offering clinicians
comprehensive orthopaedic solutions around joint reconstruction and
preservation surgeries.

 

The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's
patented dCELL® technology and is the only available, non-human biologic
graft for certain anterior cruciate ligament ('ACL') reconstruction procedures
on the market. OrthoPure® XT can also be used in the reconstruction of other
knee ligaments, including multi-ligament and primary procedures when an
autograft is not an option.

 

Richard Forster, Managing Director of Joint Operations Ltd, commented on the
agreement: "We are delighted to be working with Tissue Regenix to represent
OrthoPure® XT in the UK. As a company, we spend a great deal of time in
ligament reconstructive surgery, and it is tremendously exciting to have a
unique xenograft option to offer UK surgeons. In particular, we have been
impressed by the quality of clinical outcomes being achieved through the
Tissue Regenix clinical studies, and we look forward to these results being
replicated nationwide over the coming years."

 

Daniel Lee, Chief Executive Officer of Tissue Regenix, said: "We are excited
to partner with Joint Operations, who are experts in the distribution of
orthopaedic equipment within the UK where an estimated 30,000 ACL surgeries
take place each year(1). This strategic partnership will continue our reach
into the UK, ensuring these markets have access to our pioneering medical
technology, which will help to transform patient care."

 

(1) Beard, DJ. SNNAP Trial NDorms Oxford The Lancet, August 2022;
https://www.ndorms.ox.ac.uk/news/ACL-SSNAP-trial-results
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ndorms.ox.ac.uk_news_ACL-2DSSNAP-2Dtrial-2Dresults&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=iNbX48l719mEyjMs6BoNr9BkF1WedawtXoR8usBBMjw&m=Qc8zgvIbd2ooQP9-YRJqyz76EO7bbB4C6hVywSDOVEQ&s=ZhS_8ygusvcBi4Amt69VBU3QKYgMTNK2EGNMBc9XwxU&e=)

 

For more information:

 

 Tissue Regenix Group plc                                               www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                    via Walbrook PR

 finnCap Ltd (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780
 Alice Woodings/Lianne Applegarth   TissueRegenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRRLMPTMTIMBFJ